J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline

J&J has agreed to buy Firefly Bio for $1bn in cash, aiming to strengthen its oncology pipeline with Firefly Bio’s Firelink DAC platform. The transaction is expected to close later this year, subject to regulatory approvals and other customary closing conditions. Firefly Bio is focused on advancing its Firelink DAC platform in cancer indications where treatment options remain limited. Credit: Michael Vi / Shutterstock.com. Johnson & Johnson (J&J) has agreed to purchase Firefly Bio for $1bn in cash, aiming to strengthen its oncology pipeline with Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) platform. The deal centres on enhancing targeted treatments…

Source: Pharmaceutical Technology